Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S.

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be unaffected.

Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...